Payment overview · 2025
General Payments
$326.85
19 reported records · 10 companies
Healthcare provider profile · identity verified
Michael J Kenneson, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · CLINTON TWP, MI · NPI 1154391969
Verified facts
What the public records show
CMS Open Payments records show Michael J Kenneson, D.O. received $326.85 in general payments during 2025 across 19 reported records.
Amgen Inc. accounted for 23.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Shingrix, Trelegy Ellipta.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Myrbetriq by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 113 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 153 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 118 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $76.01 | 23.3% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $64.75 | 19.8% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $47.92 | 14.7% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $34.46 | 10.5% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $25.25 | 7.7% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $19.14 | 5.9% | 1 | 2025 |
| Intra-Sana Laboratories | Unresolved — no canonical attribution shown | $15.44 | 4.7% | 1 | 2025 |
| Dynavax Technologies Corporation | Unresolved — no canonical attribution shown | $15.15 | 4.6% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$14.38 | 4.4% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.35 | 4.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $326.85 | 19 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $60.00 | 4 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $44.60 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $44.60 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $44.60 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $34.46 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $33.23 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $30.00 | 2 | 2025 |
Source payment records
|
|||||
| General - Pain Management Normalized: general pain management |
Device | Boston Scientific Corporation | $25.25 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $20.15 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $20.15 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $19.14 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $16.01 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $16.01 | 1 | 2025 |
Source payment records
|
|||||
| GLYCATE Normalized: glycate |
Drug | Intra-Sana Laboratories | $15.44 | 1 | 2025 |
Source payment records
|
|||||
| RELTONE 200 MG Normalized: reltone 200 mg |
Drug | Intra-Sana Laboratories | $15.44 | 1 | 2025 |
Source payment records
|
|||||
| RELTONE 400 MG Normalized: reltone 400 mg |
Drug | Intra-Sana Laboratories | $15.44 | 1 | 2025 |
Source payment records
|
|||||
| Heplisav-B Normalized: heplisav b |
Drug | Dynavax Technologies Corporation | $15.15 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $14.69 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $14.69 | 1 | 2025 |
Source payment records
|
|||||
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $14.38 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.35 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.35 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 49 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 153 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 42 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 113 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
42 | 35 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
113 | 35 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
38 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
153 | 45 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
118 | 29 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 775 | 205 |
| Lisinopril | Lisinopril | 674 | 194 |
| Atorvastatin Calcium | Atorvastatin Calcium | 639 | 189 |
| Amlodipine Besylate | Amlodipine Besylate | 471 | 135 |
| Omeprazole | Omeprazole | 470 | 147 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 440 | 134 |
| Alprazolam | Alprazolam | 372 | 72 |
| Losartan Potassium | Losartan Potassium | 356 | 107 |
| Metoprolol Succinate | Metoprolol Succinate | 304 | 87 |
| Atenolol | Atenolol | 274 | 78 |
| Sertraline Hcl | Sertraline Hcl | 259 | 81 |
| Meloxicam | Meloxicam | 255 | 95 |
| Trazodone Hcl | Trazodone Hcl | 247 | 82 |
| Metformin Hcl | Metformin Hcl | 244 | 71 |
| Tamsulosin Hcl | Tamsulosin Hcl | 226 | 66 |
| Metformin Hcl Er | Metformin Hcl | 191 | 56 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 189 | 56 |
| Allopurinol | Allopurinol | 188 | 50 |
| Famotidine | Famotidine | 187 | 64 |
| Gabapentin | Gabapentin | 187 | 80 |
| Montelukast Sodium | Montelukast Sodium | 175 | 51 |
| Simvastatin | Simvastatin | 167 | 44 |
| Pantoprazole Sodium | Pantoprazole Sodium | 162 | 55 |
| Ezetimibe | Ezetimibe | 155 | 42 |
| Furosemide | Furosemide | 153 | 49 |
| Ozempic | Semaglutide | 153 | 45 |
| Pioglitazone Hcl | Pioglitazone Hcl | 151 | 47 |
| Metoprolol Tartrate | Metoprolol Tartrate | 136 | 41 |
| Donepezil Hcl | Donepezil Hcl | 132 | 49 |
| Potassium Chloride | Potassium Chloride | 131 | 43 |
| Duloxetine Hcl | Duloxetine Hcl | 128 | 40 |
| Azithromycin | Azithromycin | 125 | 94 |
| Doxycycline Hyclate | Doxycycline Hyclate | 125 | 92 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 121 | 34 |
| Eliquis | Apixaban | 118 | 29 |
| Alendronate Sodium | Alendronate Sodium | 116 | 46 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 115 | 85 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 113 | 35 |
| Methylprednisolone | Methylprednisolone | 103 | 89 |
| Hydrochlorothiazide | Hydrochlorothiazide | 89 | 30 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 89 | 53 |
| Hydralazine Hcl | Hydralazine Hcl | 86 | 28 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 84 | 25 |
| Pravastatin Sodium | Pravastatin Sodium | 81 | 19 |
| Baclofen | Baclofen | 80 | 38 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 80 | 22 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 78 | 28 |
| Tramadol Hcl | Tramadol Hcl | 77 | 35 |
| Zolpidem Tartrate | Zolpidem Tartrate | 76 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 75 | 24 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 72 | 12 |
| Carvedilol | Carvedilol | 72 | 22 |
| Fluoxetine Hcl | Fluoxetine Hcl | 72 | 19 |
| Ibuprofen | Ibuprofen | 70 | 31 |
| Glipizide Er | Glipizide | 69 | 21 |
| Bupropion Xl | Bupropion Hcl | 66 | 20 |
| Finasteride | Finasteride | 66 | 21 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 65 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 64 | 22 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 57 | 57 |
| Xarelto | Rivaroxaban | 57 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 56 | 13 |
| Synthroid | Levothyroxine Sodium | 55 | 15 |
| Aripiprazole | Aripiprazole | 54 | 15 |
| Nystatin | Nystatin | 54 | 24 |
| Ondansetron Hcl | Ondansetron Hcl | 53 | 38 |
| Januvia | Sitagliptin Phosphate | 52 | 12 |
| Pregabalin | Pregabalin | 52 | 20 |
| Ropinirole Hcl | Ropinirole Hcl | 52 | 15 |
| Buspirone Hcl | Buspirone Hcl | 51 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 49 | 14 |
| Mounjaro | Tirzepatide | 49 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 47 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 47 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 47 | 15 |
| Lorazepam | Lorazepam | 46 | 11 |
| Lovastatin | Lovastatin | 43 | 11 |
| Terazosin Hcl | Terazosin Hcl | 43 | 11 |
| Valacyclovir | Valacyclovir Hcl | 43 | 18 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 42 | suppressed |
| Memantine Hcl | Memantine Hcl | 42 | 13 |
| Mupirocin | Mupirocin | 42 | 26 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 42 | 35 |
| Diclofenac Sodium | Diclofenac Sodium | 40 | 16 |
| Fluconazole | Fluconazole | 39 | 20 |
| Ketoconazole | Ketoconazole | 39 | 17 |
| Jardiance | Empagliflozin | 38 | 14 |
| Hydrocortisone | Hydrocortisone | 37 | 16 |
| Valsartan | Valsartan | 37 | suppressed |
| Bumetanide | Bumetanide | 34 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 34 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 32 | 28 |
| Lansoprazole | Lansoprazole | 30 | suppressed |
| Celecoxib | Celecoxib | 29 | 16 |
| Doxazosin Mesylate | Doxazosin Mesylate | 29 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 29 | 15 |
| Cephalexin | Cephalexin | 28 | 22 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 28 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 28 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 27 | 13 |
| Mirtazapine | Mirtazapine | 26 | 14 |
| Meclizine Hcl | Meclizine Hcl | 25 | 20 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 25 | 17 |
| Clonazepam | Clonazepam | 24 | suppressed |
| Spironolactone | Spironolactone | 24 | suppressed |
| Testosterone | Testosterone | 24 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 24 | suppressed |
| Torsemide | Torsemide | 23 | suppressed |
| Amoxicillin | Amoxicillin | 22 | 15 |
| Nifedipine Er | Nifedipine | 22 | suppressed |
| Trulicity | Dulaglutide | 22 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Naproxen | Naproxen | 21 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Diazepam | Diazepam | 20 | 11 |
| Enalapril Maleate | Enalapril Maleate | 20 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Myrbetriq | Mirabegron | 20 | suppressed |
| Ondansetron Odt | Ondansetron | 20 | 15 |
| Warfarin Sodium | Warfarin Sodium | 20 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 19 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 19 | suppressed |
| Topiramate | Topiramate | 19 | suppressed |
| Glimepiride | Glimepiride | 18 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 18 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 18 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 17 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 16 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 16 | suppressed |
| Estradiol | Estradiol | 16 | suppressed |
| Linzess | Linaclotide | 16 | suppressed |
| Novolog Flexpen | Insulin Aspart | 16 | suppressed |
| Tobramycin | Tobramycin | 16 | 12 |
| Colchicine | Colchicine | 15 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 15 | suppressed |
| Methocarbamol | Methocarbamol | 15 | 11 |
| Prednisone | Prednisone | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Clotrimazole | Clotrimazole | 14 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 14 | suppressed |
| Humalog | Insulin Lispro | 14 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Telmisartan | Telmisartan | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
| Tirosint | Levothyroxine Sodium | 11 | suppressed |
| Trospium Chloride Er | Trospium Chloride | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $326.85 · 19 records | Amgen Inc. | ABRYSVO, AREXVY, COMIRNATY, EVENITY, GLYCATE, General - Pain Management, Heplisav-B, INCEPTIV, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, PROLIA, RELTONE 200 MG, RELTONE 400 MG, REPATHA, SHINGRIX, TRELEGY ELLIPTA, Veozah, ZAVZPRET, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error